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Chapter 1 
1. Introduction 
 
1.1 Autoimmune Diseases of the Thyroid and Thyroid Peroxidase 
 
Autoimmune diseases of the thyroid gland affect between 2-4% of women and 1% of 
men worldwide1-4. They are generally characterized by hyperthyroidism (Graves disease) 
or hypothyroidism (Hashimoto’s thyroiditis) along with some form of enlargement 
(goitre) of the thyroid gland, resulting in hormone disruption which can lead to many 
adverse symptoms including tachycardia, tremors and glucose intolerance1,5. Both Graves 
disease and Hashimoto’s thyroiditis are propagated by the body producing antibodies that 
attack the naturally occurring thyroid products, Thyroid Stimulating Hormone (THS) and 
Thyroid Peroxidase (TPO), a surface bound enzyme6-8. In a healthy patient TPO is 
produced by the thyroid in order to catalyse certain enzymic functions such as the 
halogenation of thyroglobulin and the reaction between iodotyrosine residues to form 
thyroid hormone1,8. However, in patients with autoimmune thyroid diseases TPO 
becomes an autoantigen that stimulates a humoral immune response from anti-TPO 
antibodies (TPO aAbs), either caused by, or leading to, the aforementioned conditions7, 8. 
TPO aAbs are found in patients with both Graves’ Disease and Hashimoto’s Thyroiditis, 
with their presence detected in 75% and 90% of patients, respectively1,4. 
 Therefore, to aid in diagnosis, it has become important for there to exist a clinical 
method that can ascertain the concentration of TPO aAbs in human blood sera. This 
technique is usually a biological assay, which exist in many forms. When studying 
antibodies, assay types include,   
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(i) the simple western blot technique9 
(ii) immunoprecipitation10 
(iii) agglutination11 
(iv) immunofluorescence 12 
(v) immunoassay13, 14 
In this thesis, immunoassays are considered, more specifically, the Enzyme-Linked 
Immunosorbent Assay or ELISA. 
The concept of the immunoassay has been around since the 1960’s. The idea was 
first developed based on the need for a highly explicit, highly responsive assay for 
insulin. The methods that resulted were the original immunoassays, the 
radioimmunoassay (RIA)15 and the immunofluorescence assay (IMF)16. However, despite 
being effective in their own ways they both had serious shortcomings15, 16. It would be a 
decade until the superior ELISA technique would first be reported.  
 
1.2 The  History of Enzyme-Linked Immunosorbant Assays  
 
 The ELISA technique was first introduced between 1971 and 1972. It is based on 
the practical theories and experiments of Engvall and Perlmann who described a method 
for the analysis of the concentration of Immunoglobulin G in human sera17. The method 
involves a solid phase where the proposed antigen (or antibody) could be bound followed 
by the addition of sera for examination18. If the sera sample contained antibodies 
associated with the immobilized antigen or antibody, then they would bind the solid 
phase. This antigen/antibody surface binding is the basis of all immunoassays and occurs 
due to the ‘lock and key’ system, where the antibody contains a chemical ‘lock’ and the 
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antigen contains a specific chemical group or ‘key’ that fits this lock. In an organism the 
attached antibody is a marker indicating to the body that the antigen it is bound to should 
be destroyed i.e. it is the immune trigger17,18. In an immunoassay antibodies are bound in 
a ‘well’ to the antigen, allowing their concentration to be read. However, what makes 
ELISA so superior to other techniques is the method by which the bound analyte is read. 
In RIA for instance, the antigen of interest is measured indirectly by radio-labeling a 
known concentration of the same antigen and binding it on to a solid phase-bound 
antibody. When a sera, positive for the desired antigen, is introduced to the solid phase 
the antigen present will displace the radio-labeled versions. The concentration of 
displaced antigen is calculated by measuring the free radioactive signal. This process was 
extremely time consuming and tedious. In ELISA the concentration of the desired analyte 
is measured by adding a generic monoclonal antibody that has been conjugated to an 
enzyme. The enzyme will undergo a colour change with the addition of a simple 
substrate, allowing the concentration of bound analytes to be read.  This more accessible 
read process makes ELISA a cheap, simple and direct process, whilst only losing 
negligible amounts of specificity and sensitivity.  
This marked improvement in read methods meant that the ELISA technique was 
recognized quickly as superior to previously used tests, such as the aforementioned RIA 
and IMF. Both RIA and IMF did achieve the same goal as ELISA techniques, that being 
the detection and quantification of antibodies or antigens within human sera. However, 
IMF is time consuming and small scale with high sensitivity, whereas RIA can handle 
large scale tests, but the instruments involved were too technical and the involvement of  
isotopic reagents gave the test a poor shelf life. In short, neither test was sufficient as a 
viable, dependable and consistent clinical test19. The ELISA method combined the most 
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advantageous elements of RIA and IMF, by being responsive and reliable, as well as 
being relatively quick and cheap to produce and perform. In addition, ELISA is a highly 
adaptable test, being possible to modify the test procedure in order to detect almost any 
antigen, antibody or other protein contained within human sera. The most common types 
of ELISA technique are, 
(i) Direct ELISA 
(ii) Indirect ELISA 
(iii) Sandwich ELSIA 
(iv) Competitive ELISA.  
The latter two variants follow the same principle as direct and indirect ELISA, but 
methods are changed slightly to accommodate different types of antigen, or take different 
observations for experimental work. The direct and indirect methods only differ slightly 
in technique. Namely, when using direct ELISA the antibodies are bound to the solid 
phase and antigens are detected within sera, whereas indirect ELISA binds antigen to the 
solid phase so that antibody concentrations can be examined. 
 In the three decades since the discovery of the ELISA technique, it has been 
adapted and tested as a viable bioassay for many hundreds of antigens and antibodies. 
Such analytes include,  
(i) Cytomegalo-virus20-22 
(ii) Toxoplasmosis23-25 
(iii) Hepatitis-A26, 27 and Hepatitis-B28-30  
(iv) Rheumatoid Factor31-33  
More recently, due to various experimental and statistical analyses, the ELISA test for 
Antinuclear Antibodies (ANA) is being accepted as an increasingly valuable tool in the 
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diagnosis of many autoimmune diseases, including systemic lupus erythematosus34-36. 
However, due to the much needed specificity in ANA testing, immunofluorescence has 
remained the preferred ANA diagnostic for most clinicians. Additionally, ELISA has 
been employed in the detection of the Human Immunodeficiency Virus (HIV)37-40. It is 
this use of ELISA in HIV testing that represents the cutting edge of ELISA use. With 
techniques being developed and incorporated that use such innovation as two separate 
immunosorbent stages in order to detect all the sub-types of the HIV virus in sera37, 
combined with new ways of making recombinant proteins that the HIV virus will respond 
to on a solid phase38, 40, ELISA tests continue to make improvements to the way HIV is 
diagnosed. 
 Despite the multitude of changes to the uses for which ELISA has been utilized, 
the general methodology has remained largely unchanged since it was first introduced. In 
its current form the ELISA technique uses a polystyrene microtitre well as a solid phase, 
arranged in to a 96-well plate, allowing for multiple assays to be carried out under the 
same conditions in a short space of time. It is difficult to pinpoint at which point the 
ELISA method was first conducted within microtitre wells rather than the tubes used by 
Engvall and Perlmann, but it can be safely assumed that most researchers had switched to 
the more efficient wells by 197820, 27. Other than this, the main element of the ELISA 
procedure which has changed since its introduction is the source of the material bound to 
the solid phase. In the early days of ELISA antigens and antibodies to be applied would 
have to be harvested from naturally occurring tissues, a costly and infecund process 
which restricted the development of ELISA techniques quite significantly. However, 
during the 1980’s came the full-scale introduction of recombinant biological 
materials41,42. The use of recombinant materials (rather than those harvested from living 
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tissue) involves producing many antigens and antibodies in a laboratory environment. 
Production is achieved by taking the relevant cDNA’s for that antigen or antibody and 
transplanting them into bacterium, or other suitable cells (many prokaryotic and 
eukaryotic systems have been tried14), and purifying the expressed material41, 42.  
 
1.3 ELISA as a Tool for the Quantification of TPO aAbs in Human Sera  
 
         The ELISA for TPO aAbs uses a typical indirect ELISA technique: recombinant 
TPO is bound inside microtitre wells and human sera from patients with suspected 
thyroid conditions are introduced. If TPO aAbs are present in the sera binding to the TPO 
will occur. A read step using anti-human antibody that has been enzyme linked allows the 
amount of binding that has occurred to be read. Reading occurs via a substrate that 
changes colour in the presence of the linked enzyme. The intensity of this colour is 
representative of the amount of TPO aAbs present in the sample. Intensity is then read by 
colorimitry and each well is assigned an absorbance value in optical density. In addition, 
solutions containing known concentrations of TPO aAbs are tested and a simple 
calibration curve is constructed using optical density values. The calibration curve is then 
used to calculate the relative concentration of TPO aAbs in the patient sera. The TPO 
ELISA is well established as a diagnostic process, being cited as both an experimental 
and clinical technique since the first published example of a TPO ELISA in 199243. The 
publication by Lauberg et al., demonstrated a stable ELISA for TPO aAbs with a good 
dose response and good reproducibility43. Since then the test has been used in diagnosis1, 
2 as well as in experimental work involving TPO or TPO aAbs6, 44.  
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1.4 Problems with TPO as an Analyte 
 
TPO ELISA is still an imperfect system due to the fact that information regarding 
several aspects of the test is still obscure19. Research in this area concerns two areas: role 
of the target antibody during the antigen/antibody interaction and the nature and structure 
of the TPO molecule. TPO is a large complex enzyme (approximately 104000amu) that 
consists of 933 amino acid residues in combination with a complement control protein, 
epidermal growth factor protein and a protein comparable to myeloperoxidase44, 45. Due 
to this formidable complexity and several structural idiosyncrasies its full three-
dimensional arrangement is yet to be fully elucidated. To further complicate matters there 
is also evidence to suggest that TPO exists in two isoforms, named TPO-1 and TPO-2. 
TPO-1 being the full length naturally occurring enzyme and TPO-2 being an alternatively 
spliced shorter version (833 residues)46. It is still unclear whether TPO-2 has any role in 
thyroid function, but is  expressed in the thyroid tissue of Graves’ disease patients.  
 
1.5 TPO, the Current State of Research 
 
However, there are numerous studies that reveal aspects of the TPO enzyme’s 
true nature. These mainly look at, amongst other things,  
(i) The isolation of the TPO from its native tissues45, 47. This area of research is 
largely outdated now where ELISA is concerned, as recombinant methods are 
far superior for obtaining TPO. However, harvesting native TPO still occurs, 
mainly as a source of material for research looking at TPO’s natural functions. 
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(ii) Analysis of TPO activity and role during natural enzyme reactions47, 48. The 
analysis of TPO’s natural functions is generally an in vitro examination of its 
iodinating properties or its role in catalyzing enzymatic functions.  
(iii) The region of the TPO molecule that binds antigenically (the epitope or 
immunodominant region (IDR))8, 44, 49, 50. The search for the TPO IDR and its 
activity is an area of considerable interest to modern science, it is hoped that 
analysis of this aspect of the TPO molecule will shed light on the causes of 
Graves’ disease and Hashimoto’s thyroiditis, eventually leading to causes and 
treatments.  
(iv) The gene sequence that codes for TPO production14, 41, 42, 51-53. These 
sequences concerns are essential for the production of recombinant TPO.  
In addition, there is also some data on the activity of TPO when binding with it’s 
associated aAbs within the ELISA well44. Work carried out by Bresson et al. showed that 
TPO’s IDR is split into two regions (IDR/A and IDR/B)44. Each region has aAbs that 
bind with more affinity to one particular region, but in more advanced stages of 
autoimmune thyroid disease the surface of the TPO molcules become increasingly more 
antigenic. It is also shown in the same paper that the varying specificity of TPO aAbs 
corresponds to a varying binding activity on the surface of the plate. It is also indicated 
that, generally, when increasing the concentration of TPO aAbs in a antibody calibrator 
by one order of magnitude should result in an increase in one unit of absorbance, giving 
sigmoidal calibration curve shapes, flattening at around three orders of magnitude. 
Bresson’s work aside, very few studies exist that observe TPO  within an ELISA 
environment, making it difficult to predict its behavior in such situations. 
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 To summarise, it can be observed from current literature that the ELISA method 
for antibody detection is a much tested and useful technique. However, when used to 
detect the antibodies associated with autoimmune thyroid disease (i.e. TPO aAbs) then 
there are still many areas of knowledge that are unclear and require further research.  
 
1.6 Indirect ELISA Process 
 
The indirect ELISA method is described. Like all ELISA techniques the indirect version 
relies on the specific binding of antibodies in human sera to the antigen bound to the solid 
phase of the test, in the case of this project, the surface of a microtitre well. The following 
set of steps describe the current indirect ELISA process (experimentally, the specifics of 
each step will be described in Chapter 2) A pictorial presentation of indirect ELISA Steps 
1-7 can be found in figure 1 with details of each step below. Steps 1-3 concern the 
preparation for the assay (i.e. production of assay plates) and Steps 4-8 concern the assay 
proper. 
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Figure 1. A schematic representation of the Indirect ELISA process. 
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Assay Preparation: 
Step 1. Irradiation: The first stage of the ELISA process requires the solid phase. 
In most cases this is a microtitre plate (figure 2) that consists of 96 polystyrene 
wells (figure 3). The polystyrene wells are then irradiated with a source of beta 
radiation. The radiation creates positive surface charge within the well, caused by 
the reaction shown in figure 4. 
 
            Figure 2. 96 well microtitre plate 
 
 
            
            Figure 3. 1 microtitre well 
                         
Figure 4. Irradiated polystyrene on the surface of the microtitre well containing positive charge to 
allow adsorption of antigen. 
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Step 2. Coating buffer addition: The target antigen is diluted in an appropriate 
chemical buffer (known as the coating buffer) and added to one of the irradiated 
plates. The antigen will undergo adsorption on to the surface of the well. 
Adsorption occurs due to negatively charged functional groups on parts of the 
TPO protein strand which allows electrostatic binding between TPO molecules 
and the well surface. 
 
Step 3. Blocking buffer addition: Following the coating stage is the blocking 
stage. The blocking stage is where a protein (usually Bovine Serum Albumin, 
BSA) is absorbed on to the well surface that is not covered by the antigen. The 
BSA is added in a second chemical buffer known as the blocking buffer. The 
process of blocking blocks the areas of the well surface where TPO is not bound 
prevents non-specific antibody binding from occurring when human sera is added. 
 
Assay: 
Step 4. Samples and antibody calibrators addition: Samples of human sera for 
testing are diluted into a chemical buffer. Antibody concentrates containing 
known amounts of antibody are diluted in to a range of concentrations to create a 
set of antibody antibody calibrators. Each sample is added to a separate well on 
the microtitre plate in duplicate. For the purpose of the TPO ELISA antibody 
calibrator concentrations are calculated in U/ml. The unit “U/ml” is a 
standardized unit indicating the relative amount of the desired antibodies that are 
present in a solution, it should be read as “Antibody Units/ml”.  Antibody 
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calibrator concentrations are usually 2700 U/ml, 900 U/ml, 300 U/ml, 100 U/ml 
and 33 U/ml.  
 
Step 5. Incubation and wash: The plate is incubated for 30 minutes at room 
temperature. Incubating the plate allows time for antibodies specific to the target 
antigen present the well to bind accordingly. Once this process is complete each 
well is thoroughly washed, this is to ensure that all unbound antibodies and other 
biological materials are removed from the well. If unbound antibodies were to 
remain in the well (sera samples are likely to contain antibodies not specific to the 
target antigen) then they would be read in the following phases of the test, giving 
a falsely elevated result.  
 
Step 6. Conjugate Antibody addition: Following the wash, the conjugate is 
added. The conjugate is anti-human Immunoglobulin G (IgG) that will bind to 
analyte antibodies (TPO aAbs in a TPO ELISA). The IgG has been conjugated 
with an enzyme that will allow the read process to take place (in this ELISA the 
enzyme is horseradish peroxidise (HRP)). This step is followed by a further 
incubation and wash as in step 5 (above). In the case of a positive ELISA test 
conjugated antibodies will bind to any TPO aAbs bound inside the well. In the 
case of a negative test the conjugated antibody will be removed with the wash. 
This discrimination means that wells containing sera that are positive for TPO 
aAbs will contain conjugated antibody. 
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Step 7. Substrate addition: Next, a substrate is added to the well. This substrate 
will undergo a redox reaction with the enzyme conjugate. The redox reaction 
between the conjugate enzyme and the substrate induces a colour change within 
the well, the intensity of which will be related to the amount of TPO aAbs. The 
substrate that is added is 3,3’,5,5’-tetramethylbenzidine (TMB)54, 55. The TMB, 
upon addition to the well, is oxidized by the H2O2 in the horseradish peroxidase 
giving the liquid in the well a blue colour. The reaction is then quenched using 
phosphoric acid. 
 
Step 8. Read and Results: Each well is read by colorimetry at 450nm. The result 
for each well is an intensity given in optical density. The relative optical intensity 
given by a well is directly proportional to the amount of TPO/TPO aAb binding 
that occurred within the well. The optical density values for each of the antibody 
calibrators is taken and used to plot a calibration curve (figure 5). 
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Figure 5. ELISA calibration curve for typical assay. Result taken from The Binding Site Ltd. ELISA for 
Tetanus toxoid.  
 
ELISA calibration curves are plotted logarithmically and favourably have a steep 
gradient as shown in figure 5. A steep gradient provides a strong positive/negative 
indication i.e. patients sera test against this curve could be clearly defined as 
positive or negative.    
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1.7 The Drawbacks of TPO ELISA 
 
The graph in figure 5 shows a typical ELISA results graph for Tetanus toxoid, the graph 
in figure 6 shows a typical ELISA result for TPO.  
 
 
Figure 6. ELISA calibration curve for typical TPO assay. 
 
It is clear from the comparison between figures 5 and 6 that the TPO ELISA has a much 
less steep gradient overall (m= 0.55). A lower value for m and flattening of the curve 
makes the test less clinically useful as there are not clearly defined positive/negative 
indicators. 
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1.8 Objectives of Study 
 
 The objective of this study, primarily, was to rectify the problem of the TPO 
ELISA calibration curve flattening shown in figure 6 in order to obtain more normal 
boundaries between positive samples and negative samples (as shown in figure 5). The 
second objective of this study was to test and analyse the reproducibility of the assay over 
time and, if necessary modify the test to improve it. 
 
This gives two objectives: 
Objective 1: To modify either the way in which the assay is produced or the way in 
which the assay is run in order for it to produce a stable and reproducible calibration 
curve with a steeper gradient similar to the one shown in figure 5.  
 
Objective 2: To analyse the reproducibility of the assay over time and, if necessary,  
modify either the way in which the assay is produced or the way in which the assay is 
run in order to improve the reproducibility of the assay. 
 
Objective 1 was tackled by modifying different areas of the test production and 
procedure. The areas studied correspond to steps outlined in section 1.6, these steps 
being,  
(i) Step 2. Coating conditions were examined. The first stage was to look at how 
changing the buffers within which TPO is bound to the solid phase affects the 
assay. 
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(ii) Step 4. Samples and Antibody calibrators. The chemical buffers that contain 
samples and antibody calibrators during the assay process were studied for their 
effect on assay performance. 
(iii) Step 6. Conjugate antibody addition. The read chemical, the conjugate antibody, 
was studied for its affect on assay performance. 
 
Objective 2 was tackled almost exclusively by looking at the antibody calibrators and 
antibody concentrates used within the test. 
Any modifications to the assay production or procedure made throughout the study in 
order to reach Objectives 1 or 2 must not change either of the following, 
 
(i) The economic feasibility of the test. Any modification made to the test, its 
production or its procedure must not increase the cost by a large margin. This 
mainly concerns increasing concentrations of expensive reagents.  
(ii) The practical feasibility of the test. For the test to sell as a product its procedure 
must adhere to a standard model. For example, changing the dilutions of antibody 
calibrators and samples or prolonging incubation times cannot be deemed 
acceptable as part of a solution to either objective. 
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Chapter 2 
2. Experimental  
 
This section will describe, firstly the traditional steps taken when producing and assaying 
a TPO ELISA test and secondly, the various modifications made to this procedure during 
the experiments conducted for this study. 
 
 2.1 Basic Method for Production of TPO Indirect ELISA Plates 
2.1.1 Method for Coating TPO ELISA Wells (Step 2, Figure 1) 
 
A solution of 2-amino-2-(hydroxymethyl)-1,3-propanediol (trizma base) (0.975g), of 
sodium chloride (NaCl) (4.5g) and sodium deoxycholate (NaDC) (0.125g) was adjusted 
to pH 8.00 by adding 5M HCl dropwise. Recombinant TPO (5µl, 1mg/ml) (Diarect AG, 
Germany) was added to the solution to give a final concentration of antigen within the 
solution of 0.2µg/ml. The solution is mixed and is known as coating buffer. The  coating 
buffer (110µl) is added to each  of the 96 wells of the microtitre plate. Plates are then 
placed in an air-tight container lined with paper towels that have been pre-saturated in 
ultra-pure water. Plates are then incubated for 24 hours at 5ºC. Following incubation the 
plates are removed from the air-tight container and the coating buffer is aspirated by 
hand. 
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2.1.2 Method for Blocking TPO ELISA Wells (Step 3, Figure 1) 
 
Stabilguard is diluted by 50% in ultra-pure water. This solution is known as the blocking 
buffer. Stabilguard is phosphate-buffered saline containing 1% BSA, as well as other 
sugars (including lactose) used in stabilizing large solid phase bound proteins (the exact 
constituents are proprietary to Diarect AG). The blocking buffer solution (100µl) is added 
to each microtitre well and left for 30 minutes. Following this the blocking buffer is 
removed and each plate is dried by placing the plates in a 37ºC incubator for 2 hours.  
 
Once dry, each plate assay plate is sealed in a sterile foil bag and stored at 5ºC before use.  
 
2.2 Basic ELISA Test Procedure 
2.2.1 Assay Preparation (Step 4, Figure 1) 
 
The assay plate must be removed from storage and left to stand (in its packaging) until 
the plate is at room temperature. During this time the antibody calibrators are produced. 
Production of antibody calibrators is achieved by taking an antibody concentrate and 
diluting it to five known concentrations (33U/ml, 100U/ml, 300U/ml, 900U/ml and 
2700U/ml of TPO aAbs). The antibody concentrate is a solution of TPO aAbs of known 
concentration refined from the blood sera of a Graves disease patient. For standard 
diluent (trizma-buffered saline (TBS) with 0.1% BSA, 0.25% sodium azide and 1% 4,5-
dichloro-2-n-octyl-isothiazolin-3-one (Kathon) and 1% polyethylene glycol (Triton X-
100)) is used to dilute all antibody calibrators. Then each sera sample (10µl) (and in-
house standard if necessary) is diluted in to sample diluent (1000µl) to give 1:100 
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solutions. Sample diluent is a similar mixture to standard diluent. Horseradish peroxidase 
(HRP) conjugated anti-human rabbit Immunoglobulin G (IgG) (10µl) is added to HRP 
conjugate diluent (200µl ultra-pure water, 10% stabilzyme, 0.45% Proclin 300 and 8% 
NaCl, 200µl) to create a 1:20 solution. This solutution is then diluted again in the same 
diluent to create a 1:20000 solution of HRP-conjugated anti-human rabbit IgG (referred 
to as conjugate antibody).  
 
2.2.2 Basic ELISA Assay Method (Steps 4-6, Figure 1) 
 
The assay plate is removed from its packaging each and antibody calibrator and diluted 
sample (100µl) is added to two separate wells in order to examine each antibody 
calibrator and sample in duplicate (Step 4, Figure 1). The loaded assay plates are placed 
in an incubator for 30 minutes at 25oC. The plate is removed and the liquid aspirated 
from each well. The wash process is performed by an automatic aspirator/dispenser. This 
device is used to wash each well with a 1% solution of tween-20. This process, known as 
the ‘wash’ process, is then repeated twice more (Step 5, Figure 1). The wash process 
serves to remove any unbound material from the well. Conjugate antibody (100µl, 
1:20000) solution is added to each well (Step 6, Figure 1) and the plate is placed in the 
incubator for a further 30 minutes at 25oC. The wash process is then repeated to remove 
any unbound conjugate antibody. After this 3,3’,5,5’-tetramethylbenzidine (TMB, 100µl) 
is added to each well (Step 7, Figure 1) and the plate is again placed in the incubator for 
30 minutes at 25oC. This stage of the process is referred to as ‘substrate addition’. When 
the plate is removed from the incubator for the final time the wells that have a positive 
response for TPO aAbs will have developed so that the liquid in the well is now blue. The 
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intensity of this colour responds to the relative concentration of TPO aAbs in the original 
sample added to that well. Phosphoric acid (100µl, 0.5M) is  added to each well in order 
to stop the reaction. The plate is then read by an absorbance colorimeter at 450nm.  Each 
well is assigned a value in optical density which is then averaged for each sample. The 
calibration curve is then constructed from the known five concentrations of the antibody 
calibrators and each sample is read from this curve.  
 
2.3 Methods for Modifications made to the TPO ELISA and Assays run to Assess 
TPO ELISA   
2.3.1 Variation of Sodium Deoxycholate Concentration (Step 2, Figure 1) 
 
Sodium deoxycholate (NaDC) (figure 7) is added in the coating buffer stage  as an agent 
that unfolds the TPO protein strand, theoretically making the antigen/antibody interaction 
more likely. Protein unfolding of this nature occurs due to the amphiphilic nature of 
NaDC. In the first stage of the project, plates were made using coating buffers with a 
range of NaDC concentration to test its affect upon assay performance and calibration 
curve shape. The concentration range consisted of 0%, 0.005%, 0.010%, 0.020%, 
0.025%, 0.030%, 0.035% and 0.050% NaDC in coating buffers (with 0.025% being 
standard). Note: concentrations are expressed in percentage by weight. 
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Production 
Eight coating buffers were made by the method in section 2.1 (250ml each). An amount 
of NaDC was added to each to make the desired concentration (i.e. to one buffer solution 
(250ml) 0.00625g of NaDC was added to create a 0.025% solution). Each coating buffer 
coated 2 ELISA plates. No other changes were made to the procedures stated in section 
2.1. 
Assay 
The 8 concentrations of NaDC (8 plates in total) were then assayed using standard 
procedures as stated in section 2.2. On each plate a antibody calibrator set of 33U/ml, 
100U/ml, 300U/ml, 900U/ml and 2700U/ml was used. Antibody calibrators were diluted 
into standard diluent. Six in-house standards (panels) were also tested to confirm the 
accuracy of the test. Panels were diluted in sample diluent. 
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Figure 7. Sodium Deoxycholate 
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2.3.2 Modification of Coating buffer from trizma-buffered saline to sodium 
carbonate  (Step 2, Figure 1) 
 
To ascertain whether the nature of the coating buffer was affecting the performance of the 
assay in any way the coating buffer was changed from the normal TBS to a NaHCO3 
solution as reported in a method by Rebuffat56.  
 
Production 
To ultra-pure water (500ml) was added sodium carbonate (0.785g), sodium hydrogen 
carbonate (1.456g) and NaDC (0.125g). The solution was then adjusted to a pH of 9.0 (as 
recommended by Rebuffat56) using 5M HCl. All other procedures for coating and 
blocking stated in section 2.1 were followed. 
 
Assay 
The plate was then assayed according to standard procedures as stated in section 2.2. As a 
comparison, a plate using a standard TBS coating buffer was assayed in parallel, using 
exactly the same test materials and antibody calibrators. On each plate a antibody 
calibrator set of 33U/ml, 100U/ml, 300U/ml, 900U/ml and 2700U/ml was used. Antibody 
calibrators were diluted into standard diluent. Six in-house standards were also tested to 
confirm the accuracy of the test. Panels were diluted in sample diluent. 
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2.3.3 Variation of Bound Antigen Concentration (Step 2, Figure 1) 
 
Testing the elevation of the concentration of antigen bound to the surface of the well was 
the next variation made to the TPO ELISA test. It was thought that by increasing the 
amount of binding occurring between the antigen and antibody the gradient of the 
calibration curve could be increased. However, this meant that the optical densities of the 
wells with higher concentrations of binding would exceed the operational limit of the 
colorimeter. Therefore, it was decided that lowering the concentration of the conjugate 
antibody solution (effectively reading less of the plate) would solve this problem. In this 
experiment plates were coated with 0.2, 0.3, 0.4 and 0.5µg/ml recombinant TPO (with 
0.2µg/ml being the standard concentration). 
 
Production 
Coating buffer solution was made according to procedure stated in section 2.1. Following 
pH adjustment the solution was split into four equal parts of 25ml. Recombinant TPO 
(1mg/ml. 5µl, 7.5µl, 10µl and 12.5µl) was added to each solution, respectively. Final 
antigen concentrations in each well were therefore 0.2, 0.3, 0.4 and 0.5µg/ml. Four blank 
microtitre plates were then coated, each with a different concentration of antigen. 
Incubation, blocking and drying then occurred according to normal procedure. 
 
Assay I 
Each plate was tested according to normal procedure with a standard antibody calibrator 
set made from antibody concentrate EQ1601 and a conjugate antibody solution of 
30 of 82 
1:20000. In-house standards were also tested on each plate. All other standard procedures 
were followed from section 2.2. 
 
Assay II 
In the second test, each plate was tested again, but this time to each plate the same 
antibody calibrator sets was assayed three times. On each was applied a different 
concentration of conjugate antibody solution. The conjugate antibody solutions used 
were 1:25000 and 1:30000 in concentration using the standard HRP-conjugated anti-
human rabbit IgG. The third conjugate antibody solution was a 1:50000 solution of the 
same type of IgG, but from a different manufacturer (Jackson Immunoresearch, U.S.A), 
who produce a more refined and responsive version of the same conjugated antibody. All 
other standard procedures were followed from section 2.2. 
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2.3.4 Modification of Sample Diluent from trizma buffered saline to 
phosphate buffered saline (Step 4, Figure 1) 
 
To determine if the contents of the sample diluent was restricting the interaction between 
TPO and TPO aAbs, assays were run to compare the traditional TBS with phosphate-
buffered saline (PBS). This test was run on plates made in sections 2.3.1 and 2.3.2 as to 
observe the effect of different diluents on plates with varying NaDC concentration and 
coating buffer. 
 
Production 
Plates from sections 2.3.1 and 2.3.2 were used. 
 
Assay 
A plate using the standard TBS coating buffer (section 2.3.1) and a plate using the 
experimental NaHCO3 coating buffer (section 2.3.2) was assayed. On each plate two 
antibody calibrator sets of 33U/ml, 100U/ml, 300U/ml, 900U/ml and 2700U/ml were 
used; one set diluted in standard diluent (TBS) and one set diluted in PBS. The PBS used 
was made from ultra-pure water with 10% NaCl, buffered with 0.25% KCl, 1% disodium 
hydrogen orthophosphate and 0.2% sodium dihydrogen orthophosphate. The solution 
also contains the same stabilizing agents and preservatives as standard diluent; namely 
BSA, Kathon and sodium azide. Six in-house standards (panels) were also tested on each 
plate to confirm the accuracy of the test. The rest of the procedures stated in section 2.2 
were followed. 
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2.3.5 Examination of Antibody Concentrates from Varying Patients (Step 
4, Figure 1) 
 
Various antibody concentrates used to produce the antibody calibrators were tested for 
differing effects on assay performance. Several different antibody concentrates were 
obtained and antibody calibrator sets made from each of them, each antibody 
concentrate coming from a different patient. The various antibody concentrates were 
coded as EQ1227 (the standard antibody concentrate), EQ1207, EQ1600, EQ1601 and 
Ha28790. All the calibration solutions were then tested on mimic plates from section 
2.3.4 as well as plates obtained from Diarect AG and plates manufactured according to 
the methods from section 2.1. 
 
Production 
Plates were manufactured according to methods in section 2.1 and section 2.3. Plates 
obtained from Diarect AG were also used. 
 
Assay 
The antibody calibrator set 33U/ml, 100U/ml, 300U/ml, 900U/ml, 2700U/ml was 
produced from each antibody concentrate (EQ1227, EQ1207, EQ1600, EQ1601 and 
Ha28790). One of each plate type (mimic, Diarect AG, standard) was then taken and the 
antibody calibrator sets made from all six antibody concentrates were tested on each 
plate. The six in-house standards (panels) were also tested on each plate. All other assay 
procedures from section 2.2 were followed. 
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2.3.6 Variation of Conjugate antibody Dilution (Step 6, Figure 1) 
 
To examine the effect of conjugate antibody solution upon assay performance, several 
assays were carried out using various antibody concentrations. A single antibody 
concentrate was used in this experiment (EQ1601). This experiment was carried out on 
plates manufactured in the standard manner.  
 
Production 
Plates were produced according to the methods in section 2.1. 
 
Assay 
A standard antibody calibrator set of 33U/ml, 100U/ml, 300U/ml, 900U/ml, 2700U/ml 
was produced from antibody concentrate EQ1601. Then four different solutions of 
conjugate antibody were produced from a standard 1:20 solution: concentrations of 
1:5000, 1:10000, 1:15000 and 1:20000 were made. Then the antibody calibrator set was 
tested four separate times on a single plate along with the in-house standards. During the 
assay process each antibody calibrator set was subjected to a different concentration of 
conjugate antibody. All other assay procedures stated in section 2.2 were followed.  
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2.3.7 Variation of Antigen Batch and Concentration (with Variation of 
Conjugate antibody Concentration) (Step 2 and 6, Figure 1) 
 
The concentration of antigen coated per well was increased again, this time to 1 and 
1.5µg/ml (five and seven times higher than normal, respectively). However, the 
concentration of the conjugate antibody solution was modified from 1:20000 to 1:100000 
to account for the increased activity; keeping optical density readings within the 
operational parameters of the colorimeter.  
 
Production 
Two plates were produced according to the method shown in section 2.3.2 one with 
1µg/ml of TPO in its coating buffer and one with 1.5µg/ml. All other standard procedures 
from section 2.1 were followed. 
 
Assay 
Each plate was tested with a standard antibody calibrator set made from antibody 
concentrate EQ1601. In-house standards were also tested on each plate. A conjugate 
antibody solution was made from IgG from Jackson Immunoresearch (U.S.A) at a 
concentration of 1:100000. All other assay procedures from section 2.2 were followed.  
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2.3.8 Production and Testing of Mimic Plates 
 
Production methods for TPO ELISA plates were acquired from Diarect AG and tested. 
Supposedly, the method suggested by Diarect AG would give a more favourable curve 
shape. In parallel, plates manufactured by Diarect AG were obtained and results were 
compared to determine whether the Diarect AG plate did have more favourable curve 
shape and whether or not it could be replicated with available materials. 
 
Production of Mimic Plates 
Plates were manufactured according to the method suggested by Diarect AG. 
 -Coating 
To ultra pure water (250ml) was added sodium chloride (2.19g), trizma base (0.304g) and 
NaDC (0.135g). The pH of the solution was then adjusted to pH 8.00 by adding 5M HCl 
dropwise. Then recombinant TPO (5µl, 1mg/ml) was added to the solution to give a final 
antigen concentration in the solution of 0.1µg/ml. The solution was thoroughly mixed 
throughout. Next, two blank microtitre plates were taken and 120µl of the coating buffer 
was added to each well. The plates were then incubated for 14 hours at 15ºC before the 
coating buffer was removed. 
 
 -Blocking 
A blocking solution of 0.5% lactose and 1% BSA in PBS (ultra-pure water with 9% 
NaCl, 3% disodium hydrogen orthophosphate and 1%  sodium dihydrogen 
orthophosphate) was adjusted to pH 7.4 was prepared for blocking. To each well blocking 
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buffer (150 µl) was added and left for 1 hour. Following this the blocking buffer was 
removed and the plates were dried in a 37ºC incubator for 2 hours.  
 
Assay I 
The mimic plate was then tested using standard procedures described in 2.2. On the plate 
a antibody calibrator set of 33U/ml, 100U/ml, 300U/ml, 900U/ml and 2700U/ml was 
used. Antibody calibrators were diluted into standard diluent. Six in-house standards 
(panels) were also tested to confirm the accuracy of the test. Panels were diluted in 
sample diluent. 
 
Assay II 
Plates manufactured by Diarect AG were then obtained and the same assay described 
above was repeated. Alongside this assay, the mimic plates from above were tested again. 
This repeat was performed because the concentration of the conjugate antibody was 
increased from 1:20000 to 1:10000 in this second test and for the purposes of fair 
comparison both plates were assayed under the same conditions. All other condition from 
the above assay and procedures stated in section 2.2 were followed. 
 
Assay III 
In addition Assay II was repeated using the conjugate antibody solution supplied by 
Diarect AG. 
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2.3.9 Analysis and Comparison of Competitors Plate 
 
To rule out the possibility that the problems observed in the TPO ELISA caused by 
something localised to the laboratory (e.g. a contaminant) several ELISA tests for TPO 
aAbs were obtained from an external source. A plate was then assayed following all of 
the manufacturer’s instructions as well as substituting all the standard diluents, antibody 
calibrators, conjugate antibody solution and other test materials for those supplied by the 
manufacturer. Further tests were then conducted to compare the performance of the 
ELISA test under study and that of the test obtained externally. 
 
Production 
Anti-TPO ELISA plates were obtained from Phadia AB (Sweden). Plates for comparison 
were manufactured according to the methods in section 2.1.  
 
Assay I 
The plate obtained from Phadia AB was tested according to the manufacturer’s 
instructions. Two supplied controls were also tested. The method for this assay was 
fundamentally the same as the procedures stated in section 2.2 with some minor changes. 
Mainly, the antibody calibrator set supplied contained six solutions of 0U/ml, 30U/ml, 
100U/ml, 300U/ml, 1000U/ml and 3000U/ml. For full details of these instructions see 
Appendix A. 
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Assay II 
To compare the two tests one plate made using standard method and one from Phadia 
were taken and tested identically. Applied to each plate were three separate antibody 
calibrator sets: one made from the standard EQ1227, one made from EQ1601 and the 
antibody calibrators supplied by Phadia. On both plates all assay materials including 
wash buffers, diluents and conjugate antibody solutions were standard as in section 2.2. 
The assay of both plates was then repeated, but in this second instance assay materials 
used were those supplied by Phadia.  
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2.3.10 Method for Assessment of TPO ELISA In-House Standards 
 
The in-house standards, which are coded P1.2, P2.2, P3.2, P4.2, P5.2 and P6.2 are fluids 
taken from a stock solution containing an exhaustively tested concentration of TPO aAbs. 
They are then tested as normal samples (i.e. diluted in sample diluent to a concentration 
of 1:100) within a TPO ELISA and are used to regulate the calibration curve. These 
standards are prepared and stored separately to other fluids used in assay procedure to 
avoid contamination. Details of each standard can be found below in Table 1. The 
coefficient of variation (CV) is a number derived by looking at the concentration value 
returned for a particular standard by several assays of the same type. Over time, this 
value should not fluctuate by more than 10%. Standards were tested over a period of 5 
days. 
Standard Dilution in assay 
Mean Concentration 
(U/ml) 
Acceptable Range 
(U/ml) 
P1.2 1:100 87 74-100 
P2.2 1:100 168 143-193 
P3.2 1:100 223 189-256 
P4.2 1:100 280 238-322 
P5.2 1:100 376 320-432 
P6.2 1:100 700 595-804 
Table 1. Concentration values for each in-house standard and the range of values an assay may return to be 
deemed acceptable. 
 
Production 
Ten assay plates were made identically according to the methods in section 2.1.  
 
Assay 
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One plate was assayed morning and afternoon for five days. All methods (indicated in 
section 2.2) were followed and all assay conditions, additives and procedures were 
followed in exactly the same manner for every assay. A new sample of each standard was 
taken for use each day (as they are stored in 100µl batches). A standard antibody 
calibrator set was produced from antibody concentrate EQ1227. In addition a 400U/ml 
solution of EQ1207 was tested on each plate. Note: a solution of 400U/ml is a positive 
control supplied with each test.  
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2.3.11 Method for Assessment of TPO ELISA Antibody concentrate 
 
A recovery test was performed on each standard listed in Table 1. In a recovery test serial 
dilutions are made from standards. For example P1.2, before an assay it is diluted just 
like a sample to make a solution of 1:100: this solution is expected to give a value of 
87U/ml. In this test however, a solution of 1:10 is made and then serially diluted to give a 
set of solutions with 1:10, 1:20, 1:40, 1:80 and 1:160 (with expected values of 
approximately 800, 400, 200, 100 and 50U/ml). A serial dilution is range is created in 
this manner for all in house standards. However, some top concentrations are adjusted to 
keep the serial within the calibration range (see Table 2). All solutions are then tested 
against the same antibody calibrator set.  
 
Production 
Plates produced according to the methods in section 2.1 were used for this test.  
Assay I 
In this first assay standard antibody concentrate EQ1227 was tested. All serial dilutions 
were tested on one plate with a antibody calibrator set made from EQ1227. Dilution 
series shown in Table 2 were made. In addition, a positive control was tested as in the 
assay from section  2.3.10. 
 
 
 
42 of 82 
 
 
 
Table 2. Showing serial dilutions made from standards in assessment of antibody concentrate EQ1227. 
Concentrations given in U/ml. 
 
 
Assay II 
In a second assay the test was repeated in a similar fashion, but this time only using a 
cross section of the standard serial dilutions (those tested are shown in Table 3). The test 
was carried out in this manner in order to fit more sets of antibody calibrators on the 
same plate. On this plate antibody calibrator sets made from EQ1600, EQ1601 and 
EQ1227 were tested along with two new antibody concentrates coded Cal5078 and 
Cal28793. All antibody calibrator sets were made to the standard concentrations. 
Performing the test in this way meant that several antibody concentrates could be 
efficiently tested for recovery. The plate was assayed according to all procedures stated in 
section 2.1. 
 
 
Standard P1.2 P2.2 P3.2 P4.2 P5.2 P6.2 
Expected 
conc. 1:100  
80 200 240 300 400 1000 
 Conc. Dil. Conc. Dil. Conc. Dil. Conc. Dil. Conc. Dil. Conc. Dil. 
Serial 
Dilutions 800 1:10 2000 1:10 2400 1:10 2000 1:15 2000 1:20 2000 1:50 
 400 1:20 1000 1:20 1200 1:20 1000 1:30 1000 1:40 1000 1:100 
 200 1:40 500 1:40 600 1:40 500 1:60 500 1:80 500 1:200 
 100 1:80 250 1:80 300 1:80 250 1:120 250 1:160 250 1:400 
 50 1:160 125 1:160 150 1:160 125 1:240 125 1:320 125 1:800 
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Standard P1.2 P3.2 P6.2 
Expected  conc. 
1:100 
80 240 1000 
 Conc. Dil. Conc. Dil. Conc. Dil. 
Serial Dilutions 800 1:10 2400 1:10 2000 1:100 
 400 1:20 1200 1:20 1000 1:200 
 200 1:40 600 1:40 500 1:400 
 100 1:80 300 1:80 250 1:800 
 50 1:160 150 1:160 125 1:1600 
Table 3. Showing serial dilutions made from standards in assessment of antibody concentrates EQ1600, 
EQ1601, EQ1227, Cal5078 and Cal28793. Concentrations given in U/ml. 
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2.3.12 Analysis of National Institute for Biological Standards and Control 
(NIBSC) Reference 
 
A nationally recognised standard was used to examine TPO antibody concentrates. A 
national standard for TPO aAbs was obtained from National Institute for Biological 
Standards and Control (NIBSC, U.K.) and tested on standard plates. A antibody 
calibrator set was made from NIBSC reference material was tested against antibody 
calibrator sets made from antibody concentrates EQ1600 and EQ1601. 
 
Production 
Plates were produced with the new TPO batch according to the methods in section 2.1. 
 
Assay 
NIBSC reference was taken and diluted (into sample diluent) to make a antibody 
calibrator set consisting of 5 solutions with concentrations 30.86U/ml, 92.59U/ml, 
277.77U/ml, 833.33U/ml and 2500U/ml. Antibody calibrator sets using antibody 
concentrates EQ1600 and EQ1601 were also made to standard concentrations. The three 
sets were then tested on a single plate along with the six in-house standards according to 
procedures from section 2.2. In parallel, the exact same antibody calibrator sets and 
standards were tested on a plate coated with the original TPO batch for added 
comparison. 
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2.3.13 Method for Fixing Antibody calibrators against NIBSC Reference 
 
A method to use the NIBSC reference material to align antibody calibrator sets with their 
correct values. Assays were run using in-house standards with an antibody calibrator set 
made from NIBSC reference. The concentrations for the in-house standards returned by 
the NIBSC reference calibration curve were considered to be taken as correct. Comparing 
the concentration values for each standard returned by the NIBSC curve with those 
returned by other antibody calibrators sets would allow an adjustment value to be 
derived. This value would then be used to adjust the concentration of the antibody 
concentrates so that the calibration curves obtained from their antibody calibrator sets 
matched the curves obtained from the NIBSC. 
Example 
The results in table 4 show the concentrations of all six standards by two different 
antibody calibrator sets.  
Antibody 
Concentrate NIBSC Reference EQ1600 
Standard Concentration (U/ml) 
P1.2 85.73 71.18 
P2.2 141.42 122.4 
P3.2 203.97 177.94 
P4.2 268.305 229.24 
P5.2 423.49 333.6 
P6.2 666.36 471.06 
Table 4. Concentration results for each standard returned by the NIBSC reference calibration and a 
calibration curve given by antibody concentrate EQ1600 
 
It is clear from the values in Table 4 that EQ1600 is returning incorrect values. Therefore 
the results are processed according to table 5. 
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  NIBSC Reference EQ1600 
Standard Concentration (U/ml) 
Adjustment Value (NIBSC concentration value/ 
Returned concentration value) 
P1.2 85.73 1.00 1.22 
P2.2 141.42 1.00 1.37 
P3.2 203.97 1.00 1.25 
P4.2 268.305 1.00 1.22 
P5.2 423.49 1.00 1.13 
P6.2 666.36 1.00 1.49 
 Mean 1.00 1.24 
Table 5. Deriving adjustment value from results in Table 4. The concentrations of standards given by the 
NIBSC calibration curve are translated as the correct values. 
 
In this scenario then, when making an antibody calibrator set from EQ1600 the initial 
dilution would be adjusted by 1.24. This change would mean that if in the assay these 
results came from EQ1600 was diluted to 1:60 to get a concentration of 2700U/ml then in 
the next assay it would be diluted to 1:75 to adjust. 
 
Production 
All plates in assays from section 2.3.14 were made according to methods stated in section 
2.1. 
Assay 
A NIBSC antibody calibrator set was produced and assayed with concentrations 
30.86U/ml, 92.59U/ml, 277.77U/ml, 833.33U/ml and 2500U/ml. The top NIBSC 
antibody calibrator (2500U/ml) was made by diluting the concentrated NIBSC solution 
by 1:200. Antibody calibrator sets of standard concentration were made from EQ1600 
and EQ1601 were also assayed. EQ1600 was diluted to a 1:60 (20.5µl in 1250µl) solution 
to create the 2700U/ml antibody calibrator and EQ1601 was diluted to 1:33 (25µl in 
840µl). NIBSC reference material and the six in-house standards were diluted into 
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sample diluent and other antibody calibrator sets were diluted into standard diluent. All 
assay procedures from section 2.2 were followed. 
 
Assay II 
Antibody calibrator sets of standard concentration were made from EQ1600, EQ1601. 
The 2700U/ml antibody calibrator for each set was made according to the following 
dilutions: EQ1600 was diluted to 1:75 (14.5µl in 1100µl) and EQ1601 was diluted to 
1:58 (15.5µl in 900µl). NIBSC reference material and the six in-house standards were 
diluted into sample diluent and other antibody calibrator sets were diluted into standard 
diluent. All assay procedures from section 2.2 were followed. 
 
Assay III 
The assay as above was repeated with the following adjustments: EQ1600 adjusted by 
1.14 to a dilution of 1:86 and EQ1601 adjusted by 1.22 to a dilution of 1:73 
 
Assay IV and V 
Assay II and then Assay III were repeated to confirm results. Antibody calibrator sets 
from EQ1600 and EQ1601 were tested twice during each repeat, once at 1:83 and once at 
1:50. The final concentration for EQ1600 was 1:75 and the final result for EQ1601 was 
1:58. 
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2.4 Materials 
2-Amino-2-(hydroxymethyl)-1,3-propanediol (trizma base) (Sigma Aldritch, Germany) 
3,3’,5,5’-Tetramethylbenzidine 
4,5-Dichloro-2-n-octyl-isothiazolin-3-one (Kathon) (Diarect AG, Germany) 
Blank 96-well Microtitre Plates (Thermo Fisher Scientific, UK) 
Bovine Serum Albumin BSA (Sigma Aldritch, Germany) 
Disodium Hydrogen Orthophosphate (Sigma Aldritch, Germany) 
Horseradish peroxidase (HRP) conjugated anti-human Immunoglobulin G (IgG) (Dako, 
Denmark) 
Horseradish peroxidase (HRP) conjugated anti-human Immunoglobulin G (IgG) (Jackson 
Immunoresearch, U.S.A) 
Hydrochloric Acid (HCl) (Sigma Aldritch, Germany) 
Phosphoric Acid (Sigma Aldritch, Germany) 
Polyethylene Glycol (Triton X-100)  
Pottasium Chloride (KCl) (Sigma Aldritch, Germany) 
Proclin 300 (Sigma Aldritch, Germany) 
Recombinant TPO (Diarect AG, Germany) 
Sodium Chloride (NaCl (Analar)) (Sigma Aldritch, Germany) 
Sodium Deoxycholate (NaDC) (Sigma Aldritch, Germany) 
Sodium Dihydrogen Orthophosphate (Sigma Aldritch, Germany) 
Stabilguard (Diarect AG, Germany) 
Stabilzyme (Diarect AG, Germany) 
Sodium Azide (Sigma Aldritch, Germany) 
Thyroid Peroxidase (TPO) (Diarect AG, Germany) 
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TPO ELISA Kit (Diarect AG, Germany) 
TPO ELISA Kit (The Binding Site, U.K.) 
TPO ELISA Kit (Varelisa, Denmark) 
Tween-20 (Sigma Aldritch, Germany) 
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Chapter 3 
3. Results and Discussion: Objective 1 
 
3.1 The Effect of Coating Conditions 
3.1.1 The Effect of NaDC Concentration in the Coating buffer (Step 2, 
Figure 1) 
 
The first experiment to examine the effect different coating buffers had on assay 
performance looked at sodium deoxycholate (NaDC, figure 7). In this experiment several 
plates were assayed with identical antibody calibrators, each plate having a different 
concentration of NaDC in its coating buffer, results are shown in figure 8. 
 
Figure 8. Graph showing how NaDC concentration to coating buffers effects assay response. Attached 
percentages show the amount of NaDC (% by weight) added to the coating buffer for each assay plate 
during production. 
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As it can be seen from figure 8 the addition of NaDC to the assay has a dramatic effect on 
response. Increasing the amount of NaDC in the coating matrix of the TPO increases the 
antigenic activity during the assay procedure and therefore the calibration gradient (by 10 
fold between 0% and 0.02% NaDC). Even at antibody calibrator concentrations of 
2700U/ml TPO aAbs the plate coated with 0% NaDC was returning values 7-8 times 
lower than the standard plate coated with 0.25%. The plate which had the standard 
0.025% NaDC returned an expected curve, similar to the one in figure 5. The effect of 
NaDC on antigen/antibody interaction is likely to occur because of the amphiphilic nature 
of NaDC. Figure 7 (page 26) shows that NaDC has a hydrophilic end, which would 
attach itself to parts of TPO and a hydrophobic end which would, at the same time, be 
dissolved in the aqueous phase, in turn unfolding the protein. To illustrate how this is so 
particularly requisite to the TPO/TPO aAb interaction a depiction of a TPO enzyme is 
shown in figure 9.   
 
This picture, although no definite conclusions can be drawn from it, shows there is the 
possibility that the immunodominant region (IDR) of the TPO molecule (the regions 
recognized by the TPO aAb) could be inaccessible or at least hindered if the protein is not 
Figure 9. Depiction of TPO 
protein. 
IDR 
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unfolded in some fashion; a theory borne out by the results is figure 8. It is also observed 
that increasing the amount of NaDC in the matrix too much starts to null the desirable 
effect that NaDC has on assay interaction. In figure 8, this seems to begin to happen after 
0.02%, with 0.025% and 0.05% giving lower responses. This effect can be seen more 
clearly in figure 10 (which includes data for plates with 0.03% and 0.035% NaDC). 
 
Figure 10. Graph showing how NaDC concentration affects the response value of each antibody 
calibrator. Labels indicate the concentration of the antibody calibrator. 
 
From the graph in figure 10 it is visible that the effect of NaDC on assay activity peaks 
and then tails of after around 0.03% NaDC in the coating buffer. The decline in activity 
could be explained by the high concentration of NaDC unfolding the protein to a point 
where it is denatured. However, the effect of NaDC also dips at around 0.025% 
unexpectedly (the results boxed on figure 10). This dip may indicate that the NaDC may 
form micelles at this concentration as reported57,62.  
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NaDC is a compound known to aggregate under certain conditions and form 
micelles57-62. In aqueous solutions these conditions seem to be optimal at pH 7.8 but no 
more than pH 8 (pH 8 being the approximate pH of coating buffers in most cases). In 
addition, it has been shown by Robinson and Tanford that amphipathic compounds tested 
(including Triton X-100, used in both standard and sample diluent) will bind to proteins 
in a desirable manner at concentrations surrounding the critical micelle concentration 
(CMC)57. Therefore, it would follow naturally that if the concentration of NaDC added to 
the coating buffer was exactly the CMC for NaDC then the unfolding effect would be 
decreased by the formation of micelles. In addition, if the work by Robinson and Tanford 
translates for TPO molecules then the optimal effect would be observed at concentrations 
slightly above and below the CMC. As shown in the work by Masuoka and Moroi the 
CMC for NaDC is dependant on the temperature of the solution62. In general the 
temperature of coating buffer solutions can be assumed to be at room temperature 
(approx. 295K). It can be seen from the graph in figure 11 that the CMC for NaDC at this 
temperature would be around 6mmol/dm3.  
54 of 82 
 
Therefore concentrations either side of the CMC should produce an optimal effect. From 
figure 10, it can be seen that an optimal effect is observed at 0.02% and 0.03% NaDC in 
coating buffers, concentrations which correspond to 4.83mmol/dm3 and 7.24mmol/dm3 
respectively. The concentration 0.025% seen to experience a deviation in the unfolding 
effect on figure 10 corresponds to concentration of 6.038mmol/dm3 and hence the CMC 
of NaDC. 
 
3.1.2 The effect of increasing Concentration of TPO in the Coating buffer 
(Step 2, Figure 1) 
 
To assess whether or not the flattening in the curve could be due to the concentration of 
TPO being coated to the inside of each well (0.2µg/ml) an experiment was conducted 
where plates were coated with increasing amounts of the antigen. The hypothesis was that 
if more antigen/antibody activity could be encouraged at higher concentrations (e.g. 
Figure 11. Graph from study by Matsuoka and Moroi62 
indicating the Critical Micelle Concentration (CMC) for 
NaDC at varying temperature. The dotted line indicates 
the CMC at temperature of 295°K. 
   RT 
6mmol dm3 
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900U/ml, 2700U/ml antibody calibrators) whilst keeping the same activity at the lower 
concentrations then a favourable steepening of the curve may be observed. Figure 12 
shows the results. 
 
Figure 12. Graph showing 4 assay calibration curves, each with a different concentration of TPO coated in 
its wells (attached values). The same antibody calibrator sets were used for each assay. The concentration 
of the conjugate antibody was 1:20000 
 
It can be seen from figure 12 that the hypothesised increase in gradient is observed. Table 
6 shows the increasing gradient of the calibration curves shown in figure 12. 
Table 6.  Gradient (m) values for curves shown in figure 12. 
 
Amount of TPO in Coating buffer (µg/ml) Calibration curve gradient (m) 
0.2 0.599 
0.3 0.717 
0.4 0.945 
0.5 1.016 
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Therefore, in the following experiment the concentration was pushed up again, to 1µg/ml 
and 1.5µg/ml. 
When preparing for the test using 1µg/ml and 1.5µg/ml coats, it was realised that 
assays coated with these higher concentrations of TPO would experience an increase in 
activity that would return optical density values likely be to be too high to be read by the 
colorimeters. Therefore, the concentration of the conjugate antibody solution used would 
be significantly reduced, lowering the overall assay response as far fewer TPO/TPO aAb 
binding situations would be read. Lowering the amount of TPO aAbs read would reduce 
overall assay response, meaning that optical density values would be in range of the 
colorimeter. Consequently, it was decided that the concentration of the conjugate 
antibody solution should be reduced from 1:20000 to 1:100000 for the assays with 1 and 
1.5µg/ml of TPO. Results for this assay are shown in figure 13 and table 7. 
 
Figure 13 Graph showing calibration curves from two assays, one with 1µg/ml TPO coated and one with 
1.5µg/ml. The same antibody calibrator sets were used for both assays. The concentration of the conjugate 
antibody solution was 1:100000. 
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Amount of TPO in Coating buffer (µg/ml) Calibration curve gradient (M) 
1 0.611 
1.5 0.640 
Table 7. Gradient (m) values for curves shown in figure 13. 
 
It can be observed from figure 13 and table 7 that increasing the antigen concentration to 
1 and 1.5µg/ml will eventually lead to a reduction in activity  
The reduction in the concentration of the conjugate antibody however, may have 
depressed the assay response and therefore the gradient. It is possible therefore, that 
coating concentrations 1µg/ml and 1.5µg/ml provide a gradient that would meet the 
expectations of Objective 1. However, increasing the antigen concentration so much 
would increase the cost of the test and modifying the conjugate antibody concentration 
changes the practical nature of the test, thus breaking both constraints listed in section 
1.8.  
 
3.2 The Effect Varying Assay Method  
3.2.1 The Effect of Different Antibody calibrator Diluents used during the 
Assay Process (Step 4, Figure 1) 
 
Two identical antibody calibrator sets were diluted into two different diluents (PBS and 
the traditionally used TBS) and assayed on the same plate. This test was conducted on 
both the standard TBS coated plate and plates with an NaHCO3 coating buffer. Results 
follow in figure 14. 
 0
0.5
1
1.5
2
2.5
3
10.00 100.00 1000.00 10000.00
Calibrator Concentration (U/ml)
O
pt
ic
al
 D
en
si
ty
 (A
U
)
1 
2 
3 
4  
 
 
Figure 14. Graph showing four calibration curves: 1, a TBS coated plate using PBS antibody calibrator 
diluent. 2, a TBS coated plate using TBS antibody calibrator diluent. 3, an NaHCO3 coated plate using 
TBS antibody calibrator diluent. 4, an NaHCO3 coated plate using PBS antibody calibrator diluent. 58 of 82 
 
The results in figure 14 show several affects. Firstly, that switching the antibody 
calibrator diluent to PBS has little effect when using the normal TBS coated plate, aside 
increasing optical response by an average of 0.23 units (trends 1 and 2). Conversely, it 
can be observed that switching to a PBS diluent actually suppresses activity when using 
the NaHCO3 coating buffer, with that antibody calibrator set giving an extremely 
shallow curve. These results indicate that the trizma base which was completely absent 
from the PBS diluted/NaHCO3 coated curve is a beneficial additive to the assay matrix, 
in both the coating buffer and the sample diluent, although more effective in the former.  
Overall it is observed that a TBS coated plate with a PBS antibody calibrator 
diluent is the most effective combination and therefore part of a solution to Objective 1. 
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3.2.2 The Effect of Modifying the Concentration of Conjugate Antibody 
(Step 6, Figure 1) 
 
It was hypothesised at this point that the flattening in the calibration curve at higher 
concentrations may be because to few of the interactions were being read. It was 
therefore decided to test this by subjecting a single antibody calibrator set to four 
different concentrations of conjugate antibody. Results from this experiment follow in 
figure 15 and table 8. 
 
Figure 15. Graph showing four calibration curves from the same antibody calibrator set on the same plate  
but subjected a different concentration of conjugate antibody. Labels indicate the concentration of 
conjugate antibody used. 
 
 
Conjugate Antibody concentration Calibration curve gradient (M) 
1:5000 1.222 
1:10000 1.104 
1:15000 0.785 
1:20000 0.618 
Table 8. Gradient (m) values for curves shown in figure 15. 
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The first thing observed from figure 15 and table 8 is that the two higher concentration 
solutions of  conjugate antibody (1:5000, 1:10000) induced such a large portion of the 
well to be read that the optical density values for the 900 and 2700U/ml antibody 
calibrators were higher than the colorimeter could read. It can be seen from table 8 
however, that these two curves had a much steeper curve up to this point, indicating that 
increasing conjugate antibody solution improves curve gradient, making increased 
conjugate antibody concentration a viable solution to Objective 1.  
Increasing conjugate antibody concentration as a method for gradient 
improvement is prevented from being tested more extensively by the fact that this would 
involve diluting the rest of the test down, and therefore, modifying the test a to too 
greater degree. Additionally, increasing conjugate antibody concentration would disrupt 
the reliability of the test, i.e. trying to detect small numbers of interactions with a large 
amount of read material would start to increase error.  
 
Having looked at Steps 2, 4 and 6 (figure 1), despite having found many useful  premises 
concerning the TPO ELISA and the improvement of its calibration curve gradient, no 
completely viable solution objective 1 that meets all the required criteria was found.  
Therefore, this area of research was abandoned in favour of analysing the tests reliability 
and reproducibility. 
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Chapter 4 
4. Results and Discussion: Objective 2 
The experiments regarding objective 2 are shown here. This section of the study concerns  
3 elements.  
1. The analysis of the TPO ELISA’s poor reproducibility over time, discussed in 
section 4.1. 
2. The discovery of the cause of the TPO ELISA’s poor reproducibility, discussed in 
section 4.2. 
3. The fixing of the TPO ELISA’s poor reproducibility using the NIBSC reference 
material discussed in section 4.3. 
 
4.1 Results pertaining to the performance of TPO ELISA In-House 
Standards 
 
This section of results considers the experiments conducted to test the reliability of the 
TPO ELISA test as stated in Objective 2. 
In order to analyse the stability of the TPO ELISA test over time, in-house 
standards were tested a total of 10 times over a period of 6 days with each assay being 
carried out under identical conditions. Results from these assays were then statistically 
analysed for variation. For each in-house standard a Coefficient of Variation (%CV) was 
calculated, to be deemed acceptable the %CV must not exceed 10%. Table 9 shows the 
results to obtained from this analysis.  
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 Standard P1.2 P2.2 P3.2 P4.2 P5.2 P6.2 
Positive 
Control 
 Time Concentration U/ml 
Day 1 AM 81.9 198.1 222.0 312.2 439.3 1058.1 524.2 
Day 2 
AM Void Void Void Void Void Void Void 
PM 81.5 142.4 260.7 362.8 330.0 1079.6 427.0 
Day 3 
AM 79.7 261.7 231.6 324.5 480.3 1170.8 530.0 
PM 85.0 260.7 235.4 315.2 453.9 978.3 458.6 
Day 4 
AM 58.7 227.4 217.8 232.1 305.8 1074.3 523.8 
PM 59.6 226.1 200.2 237.9 290.8 1017.1 512.7 
Day 5 
AM 79.9 206.3 206.1 249.1 520.6 1025.9 460.1 
PM 88.3 281.6 210.8 257.6 621.3 1222.2 486.9 
Day 6 AM 101.7 144.3 210.1 385.7 214.7 1012.7 562.9 
 
Target 
Mean 87.0 168.0 223.0 280.0 376.0 700.0 485.0 
 Mean 79.6 216.5 221.6 297.4 406.3 1071.0 498.5 
 
Standard 
Deviation 13.4 49.5 18.6 56.0 129.5 79.0 43.2 
 %CV 16.9 22.9 8.4 18.8 31.9 7.4 8.7 
 Pass/Fail F F P F F P P 
 
Table 9. Table showing results returned for each TPO in-house standard over 10 separate assays run under 
identical conditions, on plates produced by standard procedure and against antibody calibrators made from 
concentrate EQ1227.  The value ‘%CV’  (Coefficient of Variation) is calculated by dividing the standard 
deviation by the mean and multiplying by 100.  To be deemed acceptable (P) a standard must obtain >10% 
CV over 9 assays. 
 
As the results in Table 9 show, the TPO ELISA does not produce consistent results over 
time, assuming that the in-house standards are of constant concentration (only 2 out of 
the 6 standards achieved acceptable levels of variation giving the ELISA for TPO a 66% 
fail rate). To illustrate the amount that results vary over time the results for P3.2 and P5.2 
are represented in figures 16 and 17.  
 
63 of 82 
 
Figure 16. Graph showing how the concentration of standard P3.2 varied over time, P3.2 passed the 
linearity test. Error taken at 2 standard deviations. 
 
 
Figure 17. Graph showing how the concentration of standard P5.2 varied over time, P5.2 failed the 
linearity test. Error taken at 2 standard deviations. 
 
 
P3.2 
CV= 8.4% 
Pass 
P5.2 
CV= 31.9% 
Fail 
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The graphs shown in figures 16 and 17 indicate just how much the results returned over 
time can vary. It is even shown that the results vary on a day-by-day basis, but that could 
be purely coincidental and would have to be tested exhaustively to be proven. However, 
it is certain  that at least one aspect of the assay was causing considerable inconsistency 
in results over time.  In a bid to ascertain the nature of the cause and find a solution to 
this problem, tests were carried out on the antibody concentrates. These tests would 
discern whether or not it was the standards themselves that were the source of the 
inconsistency (for example, if aggregation was occurring in the standard fluid) or  
whether it was the antibody calibrators returning inconsistent curves, leading to 
inconsistent results.  
 
 
4.2 Results pertaining to the performance of Antibody concentrates 
 
In order to test whether the antibody calibrators were responsible for the obvious 
inconsistency inherent within the TPO ELISA shown in section 3.5, a recovery test was 
conducted. A recovery test involves testing a antibody concentrates ability to return 
consistent curves. In the recovery test performed, several antibody calibrator sets were 
tested against serially diluted standards. If the antibody concentrates return concentration 
values that correctly reflect their serial dilutions then it indicates that the concentrate is 
giving consistent curves.  
To illustrate how the values from the following results are calculated, and 
therefore, how they relate back to actual ELISA results and to a demonstrate how varying 
antibody calibrator curve shapes can dramatically skew results, an example set of results 
and ca re shown in figure 18 and table 10, below. 
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 18. Two identical graphs with 4 calibration curves on each. The curves A, B, C and D were returned 
ur separate antibody calibrator sets, each made from a different antibody concentrate. All four sets 
 tested on the same plate. Also tested on the plate, one in-house standard, diluted to dilution X and 
n Y (denoted), dilution Y is half the of dilution X. Results from read 1 and read  2 are shown in table 
10 (read shown as dashed lines, visual approximation only). 
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Curve A B C D 
 Concentration (U/ml) 
Read X 160 210 515 1410 
Expected Y 
(X/2) 
80 105 275 705 
Read Y 90 105 210 315 
Recovery 112.5% 100% 81.5% 44.6% 
 
 
 
The hypothetical example shown in figure 18 and table 10 demonstrate how ineffective 
calibration curves can entirely misrepresent the concentration of a sample. Tables 11, 12 
and 13, below, show the results from the examination of three antibody concentrates. The 
antibody concentrates are coded EQ1227, EQ1600 and EQ1601 and each represent sera 
taken from a different Graves disease patient. 
P3.2 P6.2 
Dilution 
Obtained 
(U/ml) 
Expected 
(U/ml) 
Recovery 
(%) Dilution 
Obtained 
(U/ml) 
Expected 
(U/ml) 
Recovery 
(%) 
1:10 903.5 903.5 100.00 1:100 845.0 845.0 100.00 
1:20 374.9 451.7 83.00 1:200 363.5 422.5 86.05 
1:40 154.5 225.8 68.39 1:400 160.3 211.2 75.89 
1:80 75.11 112.9 66.50 1:800 87.55 105.6 82.88 
1:160 35.23 56.47 62.39 1:1600 39.40 52.81 74.60 
  
Mean 
Recovery 
(%) 76.0   
Mean 
Recovery 
(%) 83.8 
 
Table 11. Showing the results of the recovery examination from standards P3.2 and P6.2. Tested against 
standard antibody concentrate EQ1227 on a plate produced by standard procedure. 
 
Table 10. Table showing results taken from figure 18, illustrating how recovery values are calculated (values 
taken approximated). 
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It can be seen from Table 11, antibody concentrate EQ1227 provides an unfavourable 
curve. The values given for both P6.2 and P3.2 show poor recovery, where halving the 
concentration in practice delivers less that half concentration from the resulting assay. 
Falling concentrations indicate that the calibration curve provided by the concentrate 
becomes unreliable. This inconsistency is inherent in the TPO ELISA, the shallow 
calibration curve and flattening at higher concentrations are likely to yield these results. 
Examination of other antibody concentrates (i.e. TPO aAbs obtained from the sera of 
other Graves disease patients) showed some similarly adverse results. 
P3.2 P6.2 
Dilution 
Obtained 
(U/ml) 
Expected 
(U/ml) 
Recovery 
(%) Dilution 
Obtained 
(U/ml) 
Expected 
(U/ml) 
Recovery 
(%) 
1:10 727.6 727.6 100.00 1:100 694.1 694.1 100.00 
1:20 376.2 363.8 103.40 1:200 367.0 347.0 105.7 
1:40 173.6 181.9 95.45 1:400 179.7 173.5 103.5 
1:80 88.92 90.96 97.76 1:800 102.2 86.76 117.8 
1:160 43.93 45.48 96.59 1:1600 48.99 43.38 112.9 
  
Mean 
Recovery 
(%) 98.64   
Mean 
Recovery 
(%) 108.0 
 
Table 12. Showing the results of the recovery examination from standards P3.2 and P6.2. Tested against 
standard antibody concentrate EQ1600 on a plate produced by standard procedure. 
 
P3.2 P6.2 
Dilution 
Obtained 
(U/ml) 
Expected 
(U/ml) 
Recovery 
(%) Dilution 
Obtained 
(U/ml) 
Expected 
(U/ml) 
Recovery 
(%) 
1:10 746.590 746.5 100.00 1:100 716.1 716.1 100.00 
1:20 421.370 373.2 112.8 1:200 412.5 358.0 115.2 
1:40 212.150 186.6 113.6 1:400 219.1 179.0 122.4 
1:80 110.590 93.32 118.5 1:800 126.9 89.51 141.8 
1:160 52.831 46.66 113.2 1:1600 59.71 44.75 133.4 
  
Mean 
Recovery 
(%) 111.6   
Mean 
Recovery 
(%) 122.5 
 
Table 13. Showing the results of the recovery examination from standards P3.2 and P6.2. Tested against 
standard antibody concentrate EQ1601 on a plate produced by standard procedure.  
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The results in Tables 11, 12 and 13 clearly show that the antibody concentrates used in 
TPO ELISA return poor calibration curves. In order to rectify this problem an outsider 
standard was obtained in order to fix antibody calibrators and standards to definite 
concentrations. 
 
4.3 Results pertaining to the use of NIBSC Reference in fixing Calibration 
 
The NIBSC (National Institute for Biological Standards and Controls) reference is a fluid 
that contains an amount of TPO aAbs that has been exhaustively tested by several 
external laboratories. It was acquired in order to fix the TPO ELISA test, this was 
achieved by constructing a antibody calibrator set from the NIBSC fluid and assaying 
against antibody calibrator sets from other concentrates as well as the in-house standards. 
The entire test was conducted on a single standard plate using standard procedures. If the 
calibration curve given by a concentrate matches the curve of the NIBSC set then that 
concentrate is functioning properly. The results from the first instance of this experiment 
are displayed in figure 19. 
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Figure 19. Graph showing three calibration curves returned from the same plate in the first NIBSC 
experiment. Labels indicate which concentrate each antibody calibrator set was constructed from. 
 
Figure 19 shows that the two antibody concentrates tested do not behave in the same way 
as the NIBSC, indicating that they should be adjusted to do so. This adjustment is 
numerated by observing the value returned for each standard by the NIBSC reference 
calibration curve. The values for the standards are then compared against the values from 
the other two curves and an adjustment value is calculated by the method shown in Table 
14.  
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Table 14. Table showing the calculation of adjustment values from the first NIBSC experiment. 
Adjustment values are calculated by dividing the value for the a standard given by the NIBSC reference by 
the standard value given by the antibody calibrator being assessed. 
 
A divergence of 1.00 indicates that the value returned by that particular calibration curve 
is 100% correct. The concentration values for each standard returned by the NIBSC curve 
is assumed to be 100% correct. A divergence value of greater than 1.00 indicates that the 
values being returned by the antibody calibrators are too low. The mean adjustment 
value are an average divergence that each antibody calibrator set has from the NIBSC 
curve.  
The mean adjustment value gleaned from this test indicated that the antibody 
calibrator sets made from concentrates EQ1600 and EQ1601 would have to be adjusted 
down in concentration by 1.24 and 1.47, respectively. This meant reducing the 
concentration of the 2700U/ml antibody calibrator from EQ1600 from a concentration of 
1:60 to 1:75 (1.e 60 multiplied by 1.24 gives the new dilution factor of 74.4 which is 
 NIBSC Reference EQ1600 EQ1601 
Standard 
  
 Concentration 
(U/ml) Average  Concentration (U/ml)  Average 
Concentration 
(U/ml)     Average 
P1.2 84.26 87.19 85.73 69.92 72.45 71.18 51.11 52.8 51.98 
P2.2 120.7 162.0 141.4 103.4 141.4 122.4 76.74 111.1 93.95 
P3.2 203.0 204.8 203.9 177.1 178.7 177.9 147.0 148.6 147.8 
P4.2 254.2 282.3 268.3 218.6 239.8 229.2 193.6 219.8 206.7 
P5.2 423.4 423.4 423.4 333.6 333.6 333.6 360.0 360.0 360.0 
P6.2 683.6 649.0 666.3 480.5 461.6 471.0 664.1 619.7 641.9 
NIBSC 
Standard 
Value   Divergence  
 
Divergence   Divergence 
85.73     1.00 
 
Adjustment Values 
 
1.22     1.67 
141.4     1.00 1.37     1.79 
203.9     1.00 1.25     1.51 
268.3     1.00 1.22     1.35 
423.4     1.00 1.13     1.04 
666.3     1.00 1.49     1.09 
Standard 
Dev.     0.00     0.13    0.30 
Mean   1.00 
Mean 
Adjustment Value 1.24   1.47 
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rounded to 1:75). EQ1601 was also adjusted accordingly. The same assay was then 
conducted again with the adjusted antibody calibrator sets, results from this assay found 
below in figure 20 and table 15 
 
Figure 20. Graph showing four calibration curves returned from the same plate in the second NIBSC 
experiment. Labels indicate which concentrate each antibody calibrator set was constructed from. 
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NIBSC Reference 
 
EQ1600 
 
EQ1601 
 
Standard 
 Concentration (U/ml) 
Average 
  Concentration (U/ml) 
 Average 
  
Concentration 
(U/ml) 
 Average  
 
P1.2 78.634 79.23 78.93 75.82 76.36 76.09 63.25 63.71 63.48 
P2.2 134.2 140.0 137.1 121.5 126.0 123.8 107.7 112.4 110.1 
P3.2 186.6 195.0 190.8 161.4 167.8 164.6 150.8 157.8 154.3 
P4.2 266.8 276.9 271.8 223.9 232.0 227.9 221.1 230.4 225.8 
P5.2 358.0 370.0 364.0 300.7 311.4 306.1 309.8 322.2 316.0 
P6.2 482.6 481.9 482.3 415.9 415.1 415.5 443.6 442.7 443.2 
NIBSC 
Standard 
Value   
Divergen
ce  
 Divergen
ce   
Divergen
ce 
78.9     1.00 
Adjustment  
Values 
1.04     1.24 
137.2     1.00 1.11     1.25 
190.8     1.00 1.16     1.24 
271.9     1.00 1.19     1.20 
364.1     1.00 1.19     1.15 
482.3     1.00 1.16     1.09 
Standard 
Dev.     0.00    0.06     0.06 
Mean   1.00 
Mean 
Adjustment Value 1.14   1.22 
Table 15. Table showing the calculation of adjustment values from the second NIBSC experiment. 
Adjustment values are calculated by dividing the value for the a standard given by the NIBSC reference by 
the standard value given by the antibody calibrator being assessed. 
 
 
The results in table 15 show that after the first adjustment, although aligning the antibody 
calibrators sets made from antibody concentrates EQ1600 and EQ1601 with the NIBSC 
calibrator set, they are still not commensurate. This finding is not portrayed in figure 22, 
which shows the NIBSC curve and the curve from EQ1600 being almost in accord with 
one another. However, the key difference between the curves is in the lower half of the 
curve (values below 500 U/ml), where the standard readings are taken, as the curves 
made from EQ1600 and EQ1601 are aligned. 
Using the results from table 15 the process was repeated, adjusting the antibody 
calibrator sets using the mean adjustment values and then running the assay again, in 
identical conditions. This assay gave the results shown in figure 21 and table 16. 
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Figure 21. Graph showing four calibration curves returned from the same plate in the third NIBSC 
experiment. Labels indicate which antibody concentrate  each antibody calibrator set was constructed 
from. 
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Table 16. Table showing the calculation of adjustment values from the third NIBSC experiment. 
Adjustment values are calculated by dividing the value for the a standard given by the NIBSC reference by 
the standard value given by the antibody calibrator being assessed. 
 
 
Even though the calibration curves do no match exactly in figure 21, mathematically the 
results in Table 13 show that antibody calibrator sets made from EQ1600 and EQ1601 
have been adjusted to concentrations commensurate with NIBSC reference. The 
conclusion that the antibody calibrators had been fixed to an accurate dilution despite the 
divergence of antibody calibrator curves in figure 21 was deemed acceptable because 
over the range of concentrations values contained within the standards (P1.2-P6.2) both 
EQ1600 and EQ1601 made accurate returns. This range of concentrations is acceptable 
because it straddles the limit of diagnosis, above which, sera is deemed ‘positive’. The 
final concentrations for EQ1600 and EQ1601 being 1:86 and 1:73, respectively.  
 NIBSC Reference EQ1600 EQ1601 
Standard 
 
Concentration 
(U/ml) 
Average 
  Concentration (U/ml) 
 Average 
  
Concentration 
(U/ml) 
 Average  
 
P1.2 75.50 78.90 77.20 73.722 77.05 75.38 76.06 79.26 77.66 
P2.2 182.1 174.9 178.5 187.35 179.2 183.3 181.2 173.6 177.4 
P3.2 162.2 161.0 161.6 165.22 164.0 164.6 160.6 159.5 160.1 
P4.2 260.3 249.9 255.1 276.13 264.1 270.1 267.7 255.4 261.5 
P5.2 235.9 289.7 262.8 248.12 310.1 279.1 239.4 303.5 271.5 
P6.2 413.0 406.3 409.7 458.18 449.7 453.9 482.0 471.0 476.5 
NIBSC 
Standard 
Value   Divergence  
 
Divergence   Divergence 
77.20     1.00 
 
Adjustment Values 
 
1.02    0.99 
178.5     1.00 0.97    1.01 
161.6     1.00 0.98    1.01 
255.1     1.00 0.94    0.98 
262.8     1.00 0.94    0.97 
409.7     1.00 0.90    0.86 
Standard 
Dev.     0.00     0.04    0.06 
Mean   1.00 
Mean 
Adjustment Value 0.97   0.99 
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The solution provided by the NIBSC reference material ultimately satisfies 
Objective 2. After adjusting the antibody concentrates to the optimal concentrations 
described above, the linearity test described in section 4.1, Table 9, in which the TPO 
ELISA achieved a 33% pass rate,  was repeated. In the repeated test the TPO ELISA 
achieved a 100% pass rate.  
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Chapter 5 
5. Conclusions 
 
The findings in the study have revealed many theories regarding the nature of the TPO 
ELISA. By assessing assay performance under varying conditions, it have been possible 
to demonstrate several paradigms concerning the calibration curve and therefore the 
antigen/antibody interaction of the TPO ELISA. 
(i) It was demonstrated in section 3.1.1 that NaDC is essential in the TPO ELISA for 
the purpose of unfolding the TPO protein. Although unfolding the protein to a 
greater degree (increasing NaDC concentration) increased curve gradient, the 
effect only extended up to 0.03% NaDC in the coating buffer. Beyong 0.03% 
NaDC the protein became unfolded to the point where it started to become 
denatured, causing its antigenic nature to fall. 
(ii) It was demonstrated in section 3.1.2 that increasing the coat concentration of TPO 
between 0 and 0.5µg/ml within the ELISA well greatly increased assay response. 
Unfortunately above 1µg/ml activity was increased beyond the operational 
parameters of the colorimeters used to read the  ELISA plate. Although increasing 
antigen concentration was a part-solution to Objective 1, the economic 
implications meant this avenue of research was discarded. 
(iii) In section 3.2 the assay method was examined. Calibrator  diluents that optimise 
assay response were recognised in a combination of TBS as a coating buffer and 
PBS as an antibody calibrator diluent. It was also discovered that increasing the 
concentration of the conjugate antibody increased calibrator curve gradient, 
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making it a possible solution to Objective 1. However, economical and practical 
implications again meant abandoning the search for a solution to Objective 1. 
To summarise these observations it is fair to say that the TPO ELISA’s combination of 
delicate responses and resistance to changing curve shape are likely drawn from the 
fundamental nature of the relationship between TPO and its antibody. When activity 
within the ELISA well increased above a certain amount, the assay would return a 
flattened curve indicating the possibility of a hindering phenomenon between TPO and 
TPO aAbs not affected by conditions and therefore difficult to investigate within an 
ELISA setting.  
 Although these findings hold scientific interest, it is unfortunate that no solutions 
to Objective 1 of the study were gleaned from them. Changing variables within test 
conditions and observing the changes in behaviour of the ELISA yielded some incite into 
the nature of TPO, TPO aAbs and their activity within an ELISA well but the restraints of 
industrial research restricted any one of the avenues being researched further. The 
conclusions to this area of the study therefore, are left somewhat unfinished. In closing, 
further study into the actions and nature of TPO and TPO aAbs, their response to 
surrounding conditions both in vivo and in vitro and their responsiveness to other agents 
such as sodium deoxycholate would be needed to more fully understand the concepts 
explored here.   
 The most useful outcome of the study, therefore, extends from the solution 
provided to Objective 2. Improvements were made to the TPO ELISA by fixing the 
inability of the TPO ELISA to return consistent results over time. This was achieved by 
fixing the antibody concentrates to their correct concentrations. Fixing the antibody 
concentrates also allowed the in-house standards to be fixed to their correct 
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concentrations. This solution to Objective 2 improved the TPO ELISA’s reproducibility 
pass rate from 33% to 100%. 
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